NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, there are only a limited number of published studies on its association with CML (Ouerhani et al., 2011; Lemos et al., 1999), and this study focuses on the impact of NAT2 (C481T (rs1799929), G590A (rs1799930), A803G (rs1208) and G857A (rs1799931) polymorphisms on the disease (Santos et al., 2016).